These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059 [TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Paukner S; Sader HS; Ivezic-Schoenfeld Z; Jones RN Antimicrob Agents Chemother; 2013 Sep; 57(9):4489-95. PubMed ID: 23836172 [TBL] [Abstract][Full Text] [Related]
16. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia. Tang HJ; Wang JH; Lai CC Medicine (Baltimore); 2020 Jul; 99(29):e21223. PubMed ID: 32702892 [TBL] [Abstract][Full Text] [Related]
17. Lefamulin: The First Systemic Pleuromutilin Antibiotic. Chahine EB; Sucher AJ Ann Pharmacother; 2020 Dec; 54(12):1203-1214. PubMed ID: 32493034 [TBL] [Abstract][Full Text] [Related]
18. A Review of Newly Approved Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: Lefamulin. Wang H; Charles CV Sr Care Pharm; 2020 Aug; 35(8):349-354. PubMed ID: 32718391 [TBL] [Abstract][Full Text] [Related]
19. A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria. Paukner S; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Yu K Future Microbiol; 2022 Apr; 17(6):397-410. PubMed ID: 35285291 [TBL] [Abstract][Full Text] [Related]
20. Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections. van Os W; Zeitlinger M J Antimicrob Chemother; 2024 Feb; 79(2):443-446. PubMed ID: 38174805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]